Short answer
Kura Oncology, Inc. (KURA) filed its Q2 2026 10-Q quarterly report on Aug 12, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $21M (up 36.5% year over year) with net income of −$68M.
Q2 2026 key financials · XBRL
- Revenue
- $21M
- +36.5% YoY · +14.3% QoQ
- Net income
- −$68M
- −3.3% YoY · +6.8% QoQ
- Operating margin
- -349.8%
- EPS (diluted)
- −$0.77
- −2.7% YoY · +7.2% QoQ
Source: XBRL data from the Kura Oncology, Inc. (KURA) Q2 2026 10-Q on SEC EDGAR. USD.
Kura Oncology, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly triggered commercialization risk: KOMZIFTI became FDA-approved in November 2025, creating first-product launch and market-acceptance exposure
- Most material update: post-approval safety data could change KOMZIFTI’s label or trigger withdrawal from the market
- Regulatory risk: FDA approval remains subject to continual review covering manufacturing, promotion, labeling and distribution
- Competitive risk: KOMZIFTI faces REVUFORJ, another FDA-approved menin inhibitor for relapsed or refractory NPM1-mutated AML
- Reimbursement risk: HHS Medicare drug-price negotiations could significantly reduce reimbursement for selected single-source drugs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Kura Oncology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.